Skip to main content
. 2013 Aug 30;15(4):1189–1199. doi: 10.1208/s12248-013-9528-9

Fig. 2.

Fig. 2

The probability of an adverse event occurring per block of 3 months given the subject has no adverse event at the current moment (P 01; top) and dose- and body-weight-normalized tacrolimus trough concentrations (bottom), stratified by CYP3A5 phenotype